Genmab to submit cancer candidate epcoritamab to the FDA before year-end

The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.

Photo: Tuala Hjarnø / Genmab / PR

During the second half of 2022, Genmab and partner Abbvie will submit an application for marketing authorization from the FDA concerning their candidate epcoritamab. The target indication is relapsed/refractory large B-cell lymphoma (LBCL).

The application will be based on the results of the partners’ Epcore study, which generated positive top-line data in April.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs